CDKN2B-AS1 and coronary artery disorder: Above all, this investigation elucidated that ANRIL could target miR‐181b to control proliferation and apoptosis of CAD cells, thereby inducing activation of NF‐κB signalling and release of inflammatory biomarkers, including IL‐6, IL‐8, NF‐κB, TNF‐α, iNOS, ICAM‐1, VCAM‐1 and COX‐2.